Skip to search formSkip to main contentSkip to account menu

BMS-911543

Known as: JAK2 Inhibitor BMS-911543 
An orally available small molecule targeting a subset of Janus-associated kinase (JAK) with potential antineoplastic activity. JAK2 inhibitor BMS… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
The development of an improved short and efficient commercial synthesis of the JAK2 inhibitor, a complex pyrrolopyridine, BMS… 
2015
2015
JAK2 kinase inhibitors are a promising new class of agents for the treatment of myeloproliferative neoplasms and have potential… 
2015
2015
BMS-911543 is a complex pyrrolopyridine investigated as a potential treatment for myeloproliferative disorders. The development… 
2015
2015
The Jak/STAT pathway is activated in human pancreatic ductal adenocarcinoma (PDAC) and cooperates with mutant Kras to drive… 
2014
2014
Imatinib Mesylate (IM) and other tyrosine kinase inhibitor (TKI) therapies have had a major impact on the treatment of chronic… 
2013
2013
Background BMS-911543 is an oral, selective small-molecule inhibitor of JAK2 (IC50=1.1nM) with potent anti-proliferative and… 
Highly Cited
2012
Highly Cited
2012
We report the characterization of BMS-911543, a potent and selective small-molecule inhibitor of the Janus kinase (JAK) family… 
Review
2012
Review
2012
JAK-STAT (Janus associated kinase-signal transducer and activator of transcription) pathway plays a critical role in transduction… 
2010
2010
Abstract 4112 We report the characterization of BMS-911543, a potent and functionally selective small molecule inhibitor of the…